About: Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis
Creator	Tsangaris, Iraklis Savva, Athina Kotanidou, Anastasia Giamarellos-Bourboulis, Evangelos Orfanos, Stylianos Akinosoglou, Karolina Gkavogianni, Theologia Gogos, Charalambos Rovina, Nikoletta Velissaris, Dimitrios Armaganidis, Apostolos Kyriazopoulou, Evdoxia Botsa, Elektra Chaloulis, Panagiotis Chassiou, Eleftheria Cullberg, Jonas-Sundén Dimopoulos, Georgios Kontouli, Christina Leventogiannis, Konstantinos Norrby-Teglund, Anna Pantazi, Aikaterini
Source	PMC
abstract	BACKGROUND: A subanalysis of a randomized clinical trial indicated sepsis survival benefit from interleukin (IL)-1 blockade in patients with features of the macrophage activation-like syndrome (MALS). This study aimed to investigate the frequency of MALS and to develop a biomarker of diagnosis and prognosis. METHODS: Patients with infections and systemic inflammatory response syndrome were assigned to one test cohort (n = 3417) and a validation cohort (n = 1704). MALS was diagnosed for patients scoring positive either for the hemophagocytic syndrome score and/or having both hepatobiliary dysfunction and disseminated intravascular coagulation. Logistic regression analysis was used to estimate the predictive value of MALS for 10-day mortality in both cohorts. Ferritin, sCD163, IL-6, IL-10, IL-18, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were measured in the blood the first 24 h; ferritin measurements were repeated in 747 patients on day 3. RESULTS: The frequency of MALS was 3.7% and 4.3% in the test and the validation cohort, respectively. In both cohorts, MALS was an independent risk factor for 10-day mortality. A ferritin level above 4420 ng/ml was accompanied by 66.7% and 66% mortality after 28 days, respectively. Ferritin levels above 4420 ng/ml were associated with an increase of IL-6, IL-18, INF-γ, and sCD163 and a decreased IL-10/TNF-α ratio, indicating predominance of pro-inflammatory phenomena. Any less than 15% decrease of ferritin on day 3 was associated with more than 90% sensitivity for unfavorable outcome after 10 days. This high mortality risk was also validated in an independent Swedish cohort (n = 109). CONCLUSIONS: MALS is an independent life-threatening entity in sepsis. Ferritin measurements can provide early diagnosis of MALS and may allow for specific treatment.
has issue date	2017-09-18(xsd:dateTime)
bibo:doi	10.1186/s12916-017-0930-5
bibo:pmid	28918754
has license	cc-by
sha1sum (hex)	2619cd7c1a20950e064d856344c67d82ad6f8631
schema:url	https://doi.org/10.1186/s12916-017-0930-5
resource representing a document's title	Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis
has PubMed Central identifier	PMC5603161
has PubMed identifier	28918754
schema:publication	BMC Med
resource representing a document's body	covid:2619cd7c1a20950e064d856344c67d82ad6f8631#body_text
is schema:about of	named entity 'estimate' named entity 'MALS' named entity 'day' named entity 'day 3' named entity 'hemophagocytic syndrome' named entity 'levels' named entity 'day 3' named entity 'blood' named entity 'investigate' named entity 'Macrophage' named entity '66.7' named entity 'ASSOCIATED WITH' named entity 'INDICATED' named entity 'ENTITY' named entity 'BACKGROUND' named entity '4420' named entity 'SYNDROME' named entity 'PREDICTIVE VALUE' named entity 'measured' named entity 'scoring' named entity 'risk factor' named entity 'infections' named entity 'measurements' named entity 'phenomena' named entity 'tumor necrosis factor alpha' named entity 'level' named entity 'risk' named entity 'early' named entity 'sepsis' named entity 'validated' named entity 'blockade' named entity 'MALS' named entity 'validation' named entity 'MALS' named entity 'systemic inflammatory response syndrome' named entity 'immunological' named entity 'TNF-α' named entity 'Logistic regression' named entity 'prognosis' named entity 'IL-6' named entity 'interferon gamma' named entity 'ferritin' named entity 'sepsis' named entity 'Swedish' named entity 'IL-10' named entity 'IFN-γ' named entity 'early diagnosis' named entity 'IL-18' named entity 'DIC' named entity 'biomarker' named entity 'immunosuppression' named entity 'correlation' named entity 'disseminated intravascular coagulation' named entity 'HBD' named entity 'intensive care units' named entity 'aspartate aminotransferase' named entity 'pro-peptide' named entity 'multiple organ dysfunction' named entity 'Ferritin' named entity 'interferon gamma' named entity 'log-rank test'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software